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Summary
Background Many patients with advanced non-small-cell lung cancer (NSCLC) receive only active supportive care 
because of poor performance status or presence of several comorbidities. We investigated whether erlotinib improves 
clinical outcome in these patients.
Methods TOPICAL was a double-blind, randomised, placebo-controlled, phase 3 trial, done at 78 centres in the UK. 
Eligibility criteria were newly diagnosed, pathologically conﬁ rmed NSCLC; stage IIIb or IV; chemotherapy naive; no 
symptomatic brain metastases; deemed unsuitable for chemotherapy because of poor (≥2) Eastern Cooperative 
Oncology Group performance status or presence of several comorbidities, or both; and estimated life expectancy of 
at least 8 weeks. Patients were randomly assigned (by phone call, in a 1:1 ratio, stratiﬁ ed by disease stage, 
performance status, smoking history, and centre, block size 10) to receive oral placebo or erlotinib (150 mg per day) 
until disease progression or unacceptable toxicity. Investigators, clinicians, and patients were masked to assignment. 
The primary endpoint was overall survival. Analyses were by intention to treat, and prespeciﬁ ed subgroup analyses 
included development of a rash due to erlotinib within 28 days of starting treatment. This study is registered, 
number ISRCTN 77383050.
Findings Between April 14, 2005, and April 1, 2009, we randomly assigned 350 patients to receive erlotinib and 320 to 
receive placebo. We followed up patients until March 31, 2011. 657 patients died; median overall survival did not diﬀ er 
between groups (erlotinib, 3·7 months, 95% CI 3·2–4·2, vs placebo, 3·6 months, 3·2–3·9; unadjusted hazard ratio 
[HR] 0·94, 95% CI 0·81–1·10, p=0·46). 59% (178 of 302) of patients assigned erlotinib and who were assessable at 
1 month developed ﬁ rst-cycle rash, which was the only independent factor associated with overall survival. Patients 
with ﬁ rst-cycle rash had better overall survival (HR 0·76, 95% CI 0·63–0·92, p=0·0058), compared with placebo. 
Compared with placebo, overall survival seemed to be worse in the group that did not develop ﬁ rst-cycle rash (1·30, 
1·05–1·61, p=0·017). Grade 3 or 4 diarrhoea was more common with erlotinib than placebo (8% [28 of 334] vs 1% 
[ four of 313], p=0·0001), as was high-grade rash (23% [79 of 334] vs 2% [ﬁ ve of 313], p<0·0001); other adverse events 
were much the same between groups.
Interpretation Patients with NSCLC who are deemed unsuitable for chemotherapy could be given erlotinib. Patients 
who develop a ﬁ rst-cycle rash should continue to receive erlotinib, whereas those who do not have a rash after 28 days 
should discontinue erlotinib, because of the possibility of decreased survival.
Funding Cancer Research UK, Roche.
Introduction
Lung cancer, the main cause of cancer-related death, 
accounts for nearly 1·4 million deaths worldwide every 
year, and has an annual incidence of more than 41 000 in 
the UK (age standardised incidence of 48 per 100 000).1 
Mortality from lung cancer accounts for more than 
452 000 deaths in China, 342 000 in Europe, and 
162 000 in the USA.1 The number of lung-cancer deaths 
in developing countries is expected to increase during 
the next few decades such that by 2030 about 70% of 
tobacco-related deaths will occur in these countries. 
About 85–90% of patients with lung cancer have 
non-small-cell lung cancer (NSCLC), with most 
presenting with advanced or meta static disease. 
Treatment guide lines recommend four to six cycles of 
ﬁ rst-line platinum-based doublet chemotherapy. How-
ever, most patients with advanced or metastatic NSCLC 
are elderly (median age 72 years2) and many receive only 
active supportive care, including palliative radiotherapy, 
because of physician choice, poor performance status, or 
presence of several comorbidities.2,3 Therefore, despite 
the recom mendation to treat these patients with 
platinum-based chemo therapy, only about 25% of elderly 
(age >65 years) US patients3 and 29% of newly diagnosed 
UK patients2 currently receive any cytotoxic treatment.
Erlotinib is an oral EGFR inhibitor that is associated 
with a signiﬁ cant survival beneﬁ t among patients with 
NSCLC when used as maintenance monotherapy after 
ﬁ rst-line chemotherapy or as second-line or third-line 
monotherapy.4–6 In chemotherapy-naive patients with 
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activating EGFR mutations, erlotinib signiﬁ cantly 
improved progression-free survival compared with 
chemotherapy.7,8
We did a large randomised trial to determine whether 
erlotinib monotherapy would be beneﬁ cial as ﬁ rst-line 
therapy in unselected patients with advanced NSCLC 
deemed unsuitable for chemotherapy.
Methods
Study design and participants
TOPICAL was a superiority phase 3, double-blind, 
randomised, placebo-controlled trial. Eligibility criteria 
were newly diagnosed, pathologically conﬁ rmed NSCLC; 
stage IIIb or IV disease; chemotherapy naive; no symp-
tomatic brain metastases; deemed unsuitable for chemo-
therapy because of poor Eastern Cooperative Oncology 
Group (ECOG) performance status (PS ≥2) or presence of 
several comorbidities (including impaired renal function 
with creatinine clearance <60 mL/min), or both; and 
estimated life expectancy of at least 8 weeks. Such patients 
do not normally receive chemotherapy. Other inclusion 
criteria were age older than 18 years, diagnosis within the 
past 62 days, able to take oral medication, and using 
eﬀ ective contraception if appropriate. Exclusion criteria 
were previous treatment with any biological anticancer 
therapy; previous palliative radiotherapy (except to bone 
metastases, within the previous 2 weeks); pregnant or 
lactating women; evidence of signiﬁ cant laboratory ﬁ nd-
ing or concurrent uncontrolled medical illness judged to 
potentially interfere with the trial treatment; and present 
treatment with a COX-2 inhibitor. We obtained multicentre 
and local research ethics approvals. All patients provided 
written informed consent.
Randomisation and masking
Randomisation was done by site staﬀ  telephoning the 
Cancer Research UK and University College London 
Cancer Trials Centre. Patients were randomised in a 
1:1 ratio to either once daily oral erlotinib (150 mg tab-
lets) or matching placebo, with a computer generated 
sequence, stratiﬁ ed by disease stage (IIIb, IV), per-
formance status (0–1, 2, 3), smoking history (never, 
current/former), and centre (78 sites), with a block size of 
10. All investigators, clinicians, and patients were masked 
to assignment. 
Procedures
Patients were to take oral erlotinib or matching placebo 
daily, 1 h or more before food, or 2 h after food. The dose 
could be reduced to 100 mg, then 50 mg in cases of 
substantial toxic eﬀ ects. Treatment continued until 
disease progression, adverse side-eﬀ ects judged by the 
treating clinician to warrant discontinuation, or patient 
withdrawal. Patients continued to receive active sup-
portive care, including palliative radiotherapy, at the 
discretion of their clinician.
The primary endpoint was overall survival, measured 
from the date of randomisation until death from 
any cause. Secondary endpoints were progression-free 
survival (time until progression or death from any 
cause), tumour response (according to Response Evalu-
ation Criteria in Solid Tumours), adverse events, and 
quality of life. Patients who survived or who did not have 
progression were censored at the date they were last 
known to be alive. 
Within 4 weeks before randomisation patients had a 
physical examination, assessment of comorbidities with 
the Charlson comorbidity index (CCI), blood count and 
biochemistry, chest radiograph, and CT of the chest and 
abdomen. Clinicians did bone and brain scans when 
clinically indicated. Patients completed quality-of-life 
assessments (European Organisation for Research and 
Treatment of Cancer QLQ C-30 and LC14, and EuroQol 
5-dimensional scale) at baseline, monthly during the 
ﬁ rst year, then 18 and 24 months after randomisation. 
Presence of several comorbidities was deﬁ ned as CCI of 
3 or more.
Clinicians did physical examinations, including 
assessment of performance status, development of 
rash, and adverse events (with National Cancer Institute 
of Canada Common Toxicity Criteria for Adverse 
Events, version 3.0), and a chest radiograph every 
month for the ﬁ rst 12 months, and every 2 months 
thereafter. We graded rash with the criteria: erythema 
alone (A), erythema with papules (B), erythema with 
papules and pustules (C), and erythema with papules 
Figure 1: Trial proﬁ le
*Patients with no recorded start date of study drug or dosing details. ECOG=Eastern Cooperative Oncology Group 
performance status. CRCL=creatinine clearance. 
350 patients assigned erlotinib
         329 received erlotinib
            16 did not start study treatment
              5 missing data*
320 patients assigned placebo
         311 received placebo
              7 did not start study treatment
              2 missing data*
670 patients randomised
39 ineligible
1 ECOG 0/1 with 
CRCL >60 mL/min
      38 >62 days of diagnosis
40 ineligible
        4 ECOG 0/1 with 
            CRCL >60 mL/min
      36 >62 days of diagnosis
350 analysed by intention to treat
Reasons for stopping
               2 still on study drug at end of follow-up
            14 completed 12 months
            40 protocol toxicity
            20 non-protocol toxicity
            16 clinical morbidity
            21 voluntary withdrawals (not toxicity)
           84 progressive disease
         126 died
              6 other
            16 never started study drug
              5 missing data
320 analysed by intention to treat
Reasons for stopping
             0 still on study drug at end of follow-up
             6 completed 12 months
           12 protocol toxicity
           13 non-protocol toxicity
              2 clinical morbidity
           26 voluntary withdrawals (not toxicity)
         119 progressive disease
         119 died
              1 unavailable
            13 other
              7 never started study drug
              2 missing data
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and conﬂ uent pustules (D). CT scans were done at 
3 and 6 months and when clinically indicated—eg, after 
abnormal chest radiographs. 
For translational research, we collected blood samples 
and diagnostic biopsy material (paraﬃ  n blocks) before 
starting treatment. Puriﬁ cation and assessment of quality 
and quantity of tumour DNA were done with Wizard 
genomic DNA puriﬁ cation kit (Promega, Madison, WI, 
USA). We used the Sequenom OncoCarta Panel v1.0 
service (Sequenom, Germany) to do a sensitive (ie, 
detection of low abundance mutations corresponding to 
mutation frequencies of up to 10%) analysis of 238 known 
cancer mutations in 19 genes, including activating EGFR 
mutations and KRAS mutations.
Statistical analysis
The target sample size was 664 patients, on the basis of 
the primary study objective to detect an increase in 1 year 
overall survival from 10% with placebo to 17·5% with 
erlotinib (equivalent to a HR of 0·75 and much the same 
as that achieved with chemotherapy vs supportive care9), 
with 90% power and 5% two-sided test of signiﬁ cance.
We did analyses (with SAS version 9.2) by intention to 
treat, with Kaplan-Meier curves and Cox proportional 
hazards regression (hazard ratios [HRs] estimated with 
Erlotinib (N=350) Placebo (N=320)
Age at randomisation
Median (years) 77 (72–82) 77 (72–81)
≥75 years 220 (63%) 203 (63%)
Sex
Men 215 (61%) 194 (61%)
Women 135 (39%) 126 (39%)
ECOG performance status
0–1 54 (15%)* 52 (16%)*
2 194 (55%) 178 (56%)
3 102 (29%) 90 (28%)
Stage
IIIb 127 (36%) 107 (33%)
IV 223 (64%) 213 (67%)
Cell type
Adenocarcinoma 133 (38%) 123 (38%)
Squamous 136 (39%) 127 (40%)
Large cell 15 (4%) 15 (5%)
Other 66 (19%) 55 (17%)
Ethnic origin
White 336 (96%) 314 (98%)
Asian 7 (2%) 3 (1%)
Other 7 (2%) 3 (1%)
Smoking status
Smoker 124 (35%) 119 (37%)
Ex-smoker 207 (59%) 183 (57%)
Never smoked 19 (5%) 18 (6%)
Median pack-years (current or 
ex-smoker)†
40 (24–60) 38 (21–55)
Total CCI‡
Median 4·0 (3–5) 4·0 (3–5)
0 3 (1%) 1 (<1%)
1 4 (1%) 6 (2%)
2 17 (5%) 18 (6%)
3 72 (21%) 70 (22%)
≥4 241 (69%) 219 (68%)
Unknown 13 (4%) 6 (2%)
Data are n (%) or median (IQR). ECOG=Eastern Cooperative Oncology Group. 
CCI=Charlson comorbidity index. *All patients with a performance score of 0–1 
had comorbidities, ie, 92% (98 of 106) had CCI scores of ≥3, 95% (101 of 106) had 
creatinine clearance <60 mL/min, and a median age of 81 years with 81% (86 of 
106) aged >75 years old. Characteristics were well balanced between groups. †One 
pack-year is deﬁ ned as 20 cigarettes (one pack) smoked per day for one year. ‡The 
CCI is measured on a 0 to 37 scale: 0 means no comorbidities whereas a high score 
suggests patients have more severe comorbidities. Patients with a score ≥4 are 
deemed to have serious comorbidity.
Table 1: Baseline characteristics Figure 2: Overall survival and progression-free survival for all patients
HR=hazard ratio.
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maximum likelihood methods), unless otherwise spe-
ciﬁ ed (the proportional hazards assumption was met for 
overall survival and progression-free survival). We used 
the maximum grade for each type of adverse event for 
each patient. We analysed quality of life with mixed 
eﬀ ects models for repeated measures with baseline 
values as a covariate. We did model adequacy checks for 
continuous variables, including those for departures 
from normality assumptions, with residual plots and 
normal probability plots. We calculated compliance to 
study treatment by dividing the total number of tablets 
taken (equivalent to number of days on study drug) by 
the number of days from randomisation to death, 
progression, or when treatment was stopped early, and 
expressed results as a percentage. Preplanned subgroup 
analyses included sex, histological examination, activ-
ating EGFR or KRAS mutation, stage, smoking status, 
ECOG score, and development of ﬁ rst-cycle rash.
This study is registered, number ISRCTN 77383050.
Role of the funding source
The trial was funded by Cancer Research UK (C1438/
A4147), with an educational grant from Roche for the 
translational studies, but neither were involved in trial 
design, data analyses or interpretation, or writing of this 
report. Additional support came from the University 
College London and University College London Hospital 
Biomedical Research Centre, who had no role in study 
design, data collection, analysis, or interpretation, or 
writing of the report. The trial sponsor was University 
College London, who were involved trial design, data 
collection, analyses, and interpretation, and writing of 
the report. SML, IK, and AH had access to the full raw 
data. The corresponding author had the ﬁ nal 
responsibility for the decision to submit for publication.
Results
We recruited 670 patients from 78 centres from the UK 
National Cancer Research Network between April 14, 
2005, and April 1, 2009. Our randomisation procedure 
gave 936 cells and by chance the ﬁ rst allocation in each 
cell for several centres was erlotinib, producing an 
imbalance in the number randomised to each group; 
350 participants were as signed to receive erlotinib and 
320 placebo (ﬁ gure 1). We followed up patients until 
March 31, 2011. Baseline characteristics were balanced, 
including the comorbidity index (table 1). 
16 patients assigned erlotinib and seven patients 
assigned placebo did not start study treatment, because 
patients had died or progressed beforehand. Compliance 
to study treatment (deﬁ ned as patients who took their 
tablets for ≥75% of the time that they were in the trial, 
until they died or stopped treatment early), was 58% 
(204 of 350) for erlotinib and 63% (203 of 320) for 
placebo (median compliance was 88% [IQR 0–98] for 
erlotinib and 86% [0–96] for placebo, appendix p 4). 
Figure 1 shows that the main reasons for stopping trial 
treatment were toxic eﬀ ects or disease progression. 
After discontinuation of study treatment, the most 
common subsequent therapy was palliative radiotherapy, 
which was given to 34% (119 of 350) of patients assigned 
erlotinib and 36% (114 of 320) of those assigned placebo. 
Only 2% (12 of 670) of patients received a tyrosine-
kinase inhibitor (n=3) or chemotherapy (n=9) after 
disease progression, seven in the placebo group and ﬁ ve 
in the erlotinib group. The only tyrosine-kinase inhibitor 
used was erlotinib.
657 patients died; 314 in the placebo group and 343 in 
the erlotinib group, with 93% (608 of 657) of deaths 
attributed to progressive disease. Figure 2 shows Kaplan-
Meier curves for overall survival and progression-free 
survival. We identiﬁ ed no diﬀ erence in overall survival 
See Online for appendix
Erlotinib (N=334) Placebo (N=313) p value
Any event (maximum grade)
1 20 (6%) 26 (8%) ··
2 28 (8%) 32 (10%) ··
3 132 (40%) 99 (32%) ··
4 120 (36%) 120 (38%) ··
Any (grade 1–4) 300 (90%) 277 (88%) 0·18
Any (grade 3–4)* 252 (75%) 219 (70%) 0·12
Any (grade 3–4) excluding rash and diarrhoea 145 (43%) 210 (67%) 0·11
Rash (maximum grade)
No rash or grade 0 67 (20%) 201 (64%) ··
A (erythema alone) 50 (15%) 33 (11%) 0·09
B (erythema with papules) 59 (18%) 8 (3%) <0·0001
C (erythema with papules and pustules) 65 (19%) 5 (2%) <0·0001
D (erythema with papules and conﬂ uent pustules) 14 (4%) 0 <0·0001
Data unavailable because of death† 36 (11%) 31 (10%) ··
Missing data‡ 43 (13%) 35 (11%) ··
Dyspnoea
Grade 3 (dyspnoea on walking ≤100 yards) 91 (27%) 87 (28%) ··
Grade 4 (dyspnoea on mild exertion) 105 (31%) 112 (36%) ··
Grade 3–4 196 (59%) 199 (64%) 0·18
Speciﬁ c adverse events (grade 3 or 4 only)
Fatigue 77 (23%) 73 (23%) ··
Diarrhoea 28 (8%) 4 (1%) <0·0001
Anorexia 18 (5%) 15 (5%) ··
Anaemia 6 (2%) 3 (1%) ··
Nausea 5 (1%) 6 (2%) ··
Pneumonitis 5 (1%) 1 (<1%) ··
Rigor chills 4 (1%) 0 ··
Stomatitis 4 (1%) 0 ··
Ocular 3 (1%) 0 ··
Vomiting 2 (1%) 1 (<1%) ··
Constipation 1 (<1%) 5 (2%) 0·08
Headache 0 2 (1%) ··
Data are n (%). *Results when all 670 patients were used were 72% for elotinib vs 69% for placebo (p=0·43). †For 
patients who died before the ﬁ rst month assessment, rash could not be recorded. ‡No rash data available at any time, 
but patient was alive for >1 month. 
Table 2: Adverse events among all patients who started study treatment
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among all patients; median overall survival was 
3·7 months (95% CI 3·2–4·2) in the erlotinib group 
versus 3·6 months (3·2–3·9) in the placebo group 
(unadjusted HR 0·94, 95% CI 0·81–1·10, p=0·46; 
adjusted HR 0·92, 0·78–1·07, p=0·31). 1 year overall 
survival was 14% (95% CI 10–18) with placebo versus 15% 
(12–19) with erlotinib.
We identiﬁ ed a signiﬁ cant improvement in progres-
sion-free survival with erlotinib (unadjusted HR 0·83, 
95% CI 0·71–0·97, p=0·019; adjusted HR 0·80, 
0·68–0·93, p=0·0054); median progression-free survival 
was 2·8 months (95% CI 2·6–3·0) with erlotinib versus 
2·6 months (2·4–2·9) with placebo (ﬁ gure 2B). Tumour 
response rates are shown in the appendix (p 5); 4% (15 of 
350) of patients in the erlotinib group and 2% (seven of 
320) of those in the placebo group had a complete or 
partial tumour response.
Among the 647 patients who started study treatment, 
the occurrence of any grade 3–4 adverse event was 75% 
(252 of 334) with erlotinib and 70% (219 of 313) with 
placebo (p=0·12, table 2). More patients assigned 
erlotinib had rash at any time and of any grade than did 
those assigned placebo (56% [188 of 334] vs 15% [46 of 
313] p<0·0001). 24% (79 of 334) of patients assigned 
erlotinib had a high-grade (C or D) rash versus 2% 
(ﬁ ve of 313) of those assigned to placebo (p<0·0001). Sig-
niﬁ cantly more patients assigned erlotinib had diarrhoea 
of grade 3–4 than did those assigned placebo (table 2). 
21% (69 of 334) of patients assigned erlotinib had 
diarrhoea of grade 1–2 versus 8% (24 of 313) for placebo 
(p<0·0001), and rash and diarrhoea mainly occurred 
within the ﬁ rst month of treatment. Other adverse events 
were much the same between the groups.
Patients assigned erlotinib had signiﬁ cantly improved 
quality of life for two of ﬁ ve functional scales (cognitive 
[p=0·0072] and physical functioning [p=0·0024]) and 
for six of 18 symptoms (pain [p=0·0018], dyspnoea 
[p<0·0001], chest pain [p<0·0001], hoarseness [p<0·0001], 
constipation [p<0·0001], and ﬁ nancial problems 
[p<0·0001]); appen dix p 6). We recorded increased 
diarrhoea (mean diﬀ erence 15·1), hair loss (12·6), sore 
mouth (6·4), and decreased constipation (–9·4) more 
frequently in patients assigned erlotinib than in those 
assigned placebo.
In prespeciﬁ ed subgroup analyses, ﬁ rst-cycle rash 
among patients assigned erlotinib was the only sig-
niﬁ cant independent factor (HR 0·24, 95% CI 0·16–0·35, 
p<0·0001; table 3) associated with overall survival, from a 
stepwise selection multivariate analysis containing rash, 
sex, histological examination, ECOG score, stage, and 
smoking status. We identiﬁ ed a clear association between 
progression-free survival and overall survival and whether 
patients assigned erlotinib developed rash or not 
(ﬁ gure 3). Patients were classiﬁ ed as having ﬁ rst-cycle 
rash (any grade) when the rash occurred within the ﬁ rst 
28 days, which was when we made the ﬁ rst assessment of 
rash. Of the 647 patients who started study treatment, 
67 who died before this assessment were excluded from 
this subgroup analysis, to avoid bias by classiﬁ cation of 
them as not having rash. 59% (178 of 302) of patients 
assigned erlotinib developed ﬁ rst-cycle rash (compared 
with 5% [15 of 278] assigned placebo), and we recorded a 
positive correlation between overall survival (p<0·0001) 
and progression-free survival (p<0·0001) with in creasing 
rash severity.
Among patients assigned erlotinib who developed rash 
(compared with all those assigned placebo), overall 
survival was signiﬁ cantly longer (HR 0·76, 95% CI 
0·63–0·92, p=0·0058), as was progression-free survival 
(0·66, 0·54–0·80, p<0·0001). Hazard ratios for patients 
assigned erlotinib who did not develop rash, compared 
with placebo, were 1·30 (95% CI 1·05–1·61, p=0·017) for 
overall survival, and 1·09 (0·89–1·36, p=0·39) for 
progression-free survival, neither of which overlapped the 
corresponding intervals for patients who were treated 
with erlotinib and developed rash, indicating that they 
were signiﬁ cantly diﬀ erent (ie, evidence for an interaction). 
Median overall survival was 6·2 months (95% CI 4·8–7·2) 
for the erlotinib and rash group, 2·9 months (2·3–3·7) for 
the erlotinib without rash group, and 4·1 months 
(3·7–4·6) for placebo. 1 year overall survival was 24% 
(95% CI 17–29) for erlotinib and rash, 10% (5–16) for 
erlotinib without rash, and 18% (12–21) for placebo. For 
erlotinib and rash compared with placebo, the number 
needed to treat to save one life at 6 months was seven and 
Hazard ratio 
(95% CI)
p value
Predictor variables for overall survival*
Rash 0·24 (0·16–0·35)‡ <0·0001
Women vs men 0·81 (0·59–1·01) 0·17
Adenocarcinoma vs non-adenocarcinoma 0·92 (0·66–1·29) 0·64
ECOG 0–1 vs 2–3 0·87 (0·53–1·40) 0·55
Stage IIIb vs IV 0·84 (0·61–1·10) 0·23
Ex-smoker vs smoker 0·92 (0·71–1·18) 0·51
Never smoker vs smoker 0·64 (0·36–1·14) 0·13
Predictor variables for progression-free survival†
Rash 0·41 (0·27–0·60)‡ <0·0001
Women vs men 0·74 (0·44–1·03) 0·058
Adenocarcinoma vs non-adenocarcinoma 0·99 (0·71–1·37) 0·95
ECOG 0–1 vs 2–3 0·91 (0·56–1·48) 0·70
Stage IIIb vs IV 0·83 (0·59–1·09) 0·21
Ex-smoker vs smoker 0·98 (0·76–1·27) 0·88
Never smoker vs smoker 0·62 (0·35–1·10) 0·10
*For overall survival, p values from overall tests were p=0·17 for sex, p=0·62 for 
ECOG, p=0·84 for histological examination, p=0·23 for stage, and p=0·35 for 
smoking status. †For progression-free survival, p values from overall tests were 
p=0·06 for sex, p=0·86 for ECOG, p=0·79 for histological examination, p=0·21 for 
stage, and p=0·28 for smoking status. ‡Result after a stepwise selection; rash 
remained the only signiﬁ cant variable in the model for overall survival and 
progression-free survival.
Table 3: Summary of multivariate analysis for overall survival and 
progression-free survival
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at 12 months was 17. Median progression-free survival was 
3·4 months (95% CI 3·1–4·0) for erlotinib and rash, 
2·5 months (2·2–2·8) for erlotinib without rash, and 
2·9 months (2·7–3·2) for placebo.
We identiﬁ ed overall survival beneﬁ ts in patients who 
developed ﬁ rst-cycle rash in all subgroups including 
those with the worst characteristics: ECOG performance 
status 3, overall survival HR 0·58 (95% CI 0·38–0·89, 
p=0·012) and progression-free survival HR 0·41 
(0·26–0·65, p<0·0001); stage IV, overall survival HR 0·66 
(0·52–0·84, p<0·0001) and progression-free survival HR 
0·56 (0·44–0·72, p=0·0009); and age 75 years or older, 
overall survival HR 0·77 (0·61–0·97, p=0·028) and 
progression-free survival HR 0·71 (0·56–0·89, p=0·0032). 
Kaplan-Meier curves for overall survival were much the 
same for patients assigned placebo who did or did not 
develop rash (p=0·35, data not shown).
Patients assigned erlotinib who developed ﬁ rst-cycle 
rash had a higher occurrence of fatigue and diarrhoea 
than did those assigned erlotinib who did not develop 
rash (appendix p 7). The proportions with grade 3–4 
fatigue were 30% (53 of 178) for erlotinib and rash, 19% 
(24 of 124) for erlotinib without rash, and 26% (72 of 278) 
for placebo. For grade 3–4 diarrhoea, the proportions 
were 11% (20 of 178) for erlotinib and rash, 6% 
(eight of 124) for erlotinib without rash, and 1% (four of 
278) for placebo. When we excluded ﬁ rst-cycle rash, the 
proportion of patients reporting at least four grade 3–4 
adverse events was 47% (84 of 178) for erlotinib and rash, 
19% (23 of 124) for erlotinib without rash, and 36% 
(99 of 278) for placebo (appendix p 8). Among patients 
assigned erlotinib who developed rash, we recorded 
much the same eﬀ ects on quality of life as we did in the 
main analysis, with dyspnoea (–9·3) and chest pain 
(–6·7) signiﬁ cantly improved compared with patients 
without rash (appendix p 9).
Appendix p 2 shows the results of the other prespeciﬁ ed 
subgroup analyses, according to the presence or absence 
of rash in participants assigned erlotinib. Among patients 
without rash, we identiﬁ ed no evidence of beneﬁ t, and 
overall survival might be worse for some subgroups, 
such as men (HR 1·52, 95% CI 1·13–2·04, p=0·0046), or 
ECOG performance status 3 (1·69, 1·11–2·58, p=0·014). 
Patients assigned erlotinib who developed rash had 
longer overall survival and progression-free survival than 
did those assigned erlotinib who did not develop rash 
irrespective of baseline charac teristics, although some 
subgroups, including women (overall survival HR 0·66, 
95% CI 0·48–0·90, p=0·0090) and patients with 
adenocarcinoma (0·55, 0·39–0·77, p=0·00049) seemed 
to have a greater beneﬁ t than did other subgroups. 
Median overall survival for erlotinib and rash versus 
placebo was 8·1 months (95% CI 6·2–10·4) versus 
4·5 months (3·9–5·6) for women, and 4·9 months 
(4·1–6·3) versus 3·8 months (3·3–4·4) for men. 
However, the interaction test between sex and treatment 
was not signiﬁ cant (p=0·29), and some of this diﬀ erence 
might be explained by a higher compliance to erlotinib in 
women (68%, 81 of 119) than in men (52%, 101 of 195). 
Appendix p 10 shows further results for overall survival 
and progression-free survival according to sex and 
histological examination.
In our biological substudy, DNA was available for 
390 patients out of 398 (58% of total study population) 
who provided material. Occurrence of the activating 
EGFR mutation in the study population was only 7% 
(28 of 390), and 19% (73 of 390) for KRAS. Of the 
28 EGFR mutation-positive samples, 11 had exon 19 
deletions, ten had a mutation at exon 21 (858Leu→Arg), 
and seven had other mutations. In these patients, median 
overall survival was 10·4 months (95% CI 5·5–15·1) for 
erlotinib (n=17) versus 3·7 months (0·3–49·3) for 
pla cebo (n=11). Median progression-free survival was 
4·8 months (1·6–8·8) for erlotinib and 2·9 months 
Figure 3: Overall survival and progression-free survival according to whether patients on erlotinib developed 
ﬁ rst-cycle rash or not 
HR=hazard ratio. 
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(0·3–10·1) for placebo. All patients with an EGFR 
mutation who were assigned erlotinib developed rash. 
Among patients with wild-type EGFR who were assigned 
erlotinib and developed rash (n=94), HR for overall 
survival was 0·86 (95% CI 0·66–1·12, p=0·27) and 
for progression-free survival was 0·69 (0·53–0·90, 
p=0·0070; appendix p 2). HR for those assigned erlotinib 
who did not develop rash (n=67) was 1·28 (0·95–1·72, 
p=0·10) for overall survival and 1·05 (0·78–1·41, p=0·74) 
for progression-free survival.
KRAS mutation-positivity was not associated with 
overall survival or progression-free survival. Among 
those who were KRAS mutation-positive, median overall 
survival was 4·2 months (95% CI 1·8–6·2) for erlotinib 
(n=35) versus 3·6 months (1·9–4·4) for placebo (n=38); 
median progression-free survival was 3·5 months 
(1·7–4·8) versus 2·7 months (1·8–3·9). Patients with 
wild-type KRAS had median overall survival of 
3·7 months (2·8–4·2) for erlotinib (n=210) versus 
3·4 months (2·7–4·3) for placebo (n=180); median 
progression-free survival was 2·7 months (2·2–2–9) for 
erlotinib and 2·6 months (2·3–2·9) for placebo. The 
presence or absence of ﬁ rst-cycle rash did not aﬀ ect the 
results (data not shown).
Discussion
First-line treatment with erlotinib did not improve overall 
survival in all unselected patients with advanced NSCLC 
deemed unsuitable for chemotherapy treatment, who 
usually have a poor prognosis (about 3–4 months median 
overall survival10). However, erlotinib did improve 
progression-free survival. Additionally, in prespeciﬁ ed 
subgroup analyses, com pared with placebo, erlotinib 
signiﬁ cantly improved both overall survival and 
progression-free survival for patients who developed a 
ﬁ rst-cycle rash; median overall survival in this group 
increased by 2·1 months, from 4·1 months to 6·2 months. 
Multivariate analysis among patients assigned erlotinib 
conﬁ rmed that rash was the only signiﬁ cant predictor of 
overall survival. First-cycle rash has been studied 
elsewhere,11 and in TOPICAL 95% of patients assigned 
erlotinib who developed rash did so within 28 days 
(much the same as 90% within 25 days in the BR.21 
study12). Rash itself might be a predictive factor, 
irrespective of treatment. However, few patients assigned 
placebo developed ﬁ rst-cycle rash (5% compared with 
59% assigned erlotinib), and we identiﬁ ed no diﬀ erence 
in survival in patients assigned placebo who had rash 
compared with those who did not. Few patients were lost 
to follow-up because survival is short and patients with 
lung cancer in the UK are seen regularly and remain 
under the care of a hospital physician.
A limitation of our study was that the incidence of 
EGFR mutation was only 7% and a quarter of them 
were uncommon mutations. Most EGFR mutation 
studies focus on so-called hot spot analysis, looking 
only for common alterations, short deletions in exon 19, 
or the 858Leu→Arg point mutation in exon 21. Our 
population were mostly elderly, white, present or ex-
smokers, and such groups might have a diﬀ erent 
mutation spectrum proﬁ le, which further studies could 
examine. Never theless, although analyses were based 
on only 28 patients, overall survival and progression-
free survival were improved in patients with an EGFR 
mutation who were assigned erlotinib, consistent with 
geﬁ tinib in patients with poor performance status.13 
However, patients with tumours showing wild-type 
EGFR also showed beneﬁ t when they developed an 
erlotinib-related rash. The BR.216 (second and third line 
treatment) and SATURN5 trials (maintenance erlotinib 
after ﬁ rst-line chemotherapy), similarly reported that 
erlotinib was eﬀ ective in pre dominantly good perfor-
mance patients with wild-type EGFR (though BR.21 
included some patients with performance status 2–3). 
We planned TOPICAL in 2002, and did not mandate 
compulsory tissue collection. In the IPASS study,14 only 
56% (683) of patients provided samples with EGFR 
mutation data available in 36% (437) of the 1217 patients 
randomised. This proportion was much the same as in 
our trial where samples from 58% of patients  had 
suﬃ  cient DNA for analysis.
Another limitation of our study is that we did routine 
CT scans at 3 and 6 months, whereas some other 
studies have used CT scans every 6–8 weeks, so our 
schedule might be deemed suboptimum for assessment 
of progression-free survival. However, the monthly 
chest radiographs would trigger a CT scan before the 
protocol timelines, and overall survival was the primary 
trial endpoint. Also, we included patients of 
performance status 2, for whom, on the basis of 
evidence reported in 2005,15 chemotherapy could 
improve survival, and a phase 2 study16 has shown that 
doublet chemotherapy has a better survival than single 
agent chemotherapy. However, when TOPICAL was 
designed, provision of chemotherapy to such patients 
was not routine practice because many studies with 
second and third generation chemotherapy had not 
shown survival beneﬁ t, and many of these patients had 
serious adverse events.17,18 A limitation of many of the 
more recent chemotherapy trials is that median age of 
patients of performance status 2 is 65 years or younger, 
median survival is much the same as for patients of 
performance status 0–1, and many go on to receive 
second-line treatment, suggesting that they are a highly 
selected group. By contrast, in TOPICAL median age 
was 77 years, 90% of participants had several 
comorbidities, and less than 2% were given second-line 
treatment, which is indicative of the real-world scenario 
that lung cancer is a disease of elderly people with 
comorbidities, and many of these patients still continue 
to be treated with best supportive care worldwide, 
including palliative radiotherapy.19
When TOPICAL was designed some evidence already 
suggested that development of a rash during erlotinib 
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therapy could be associated with improved outcomes 
across several cancers including NSCLC.20 With this 
knowledge, we developed a scoring system for rash as 
part of the TOPICAL protocol, and speciﬁ ed a pre-
planned subgroup analysis. Our phase 3 results conﬁ rm 
these early ﬁ ndings. Furthermore, retrospective analy-
ses of two phase 3 NSCLC trials show a positive 
correlation between rash and treatment eﬀ ect on 
survival: the BR.21 trial12 of erlotinib and the FLEX trial11 
of cetuximab, an anti-EGFR antibody, when added to 
ﬁ rst-line chemotherapy. Researchers have recorded 
much the same ﬁ ndings in trials of pancreatic cancer, 
locally advanced head and neck cancer, and metastatic 
colorectal cancer.12,21,22 Currently no clear biological 
explanations link erlotinib activity with rash, but rash 
probably represents greater uptake of the drug. Smokers 
have a lower plasma concentration of erlotinib than do 
non-smokers.23,24 Smokers also have a lower incidence of 
skin rash and have less clinical beneﬁ t from EGFR 
inhibitors  compared with non-smokers.23,24 This ﬁ nding 
was conﬁ rmed in TOPICAL because present smokers in 
the erlotinib group were less likely to develop rash 
when compared with former smokers (odds ratio 0·29, 
95% CI 0·18–0·48) or never-smokers (0·20, 0·06–0·66). 
Increased occurrence of skin rash has been identiﬁ ed in 
a phase 2 dose escalation study of erlotinib, although 
another study suggested that dose-escalation does not 
improve incidence or out come.25,26 Alternatively, skin 
rash might be a surrogate marker of patients able to 
mount antitumour immune response. Data increasingly 
suggest the importance of the host immune system in 
control of cancer cell growth after tyrosine-kinase 
inhibitor treatments.27,28 As reported with other tyrosine-
kinase inhibitors, erlotinib could enhance cytotoxic 
T-cell inﬁ ltration.
Drug uptake and cytotoxic T-cell inﬁ ltration could be 
linked, with increased uptake of drug causing increased 
EGFR blockade and cell killing, resulting in improved 
host immune response. Future studies could examine 
whether combining erlotinib and immunomodulatory 
agents can further fuel a more robust immunological 
response, increase the severity and incidence of skin 
rash, and potentially further improve durability of 
response, progression-free survival, and overall survival 
in this group of patients who are deemed not suitable 
for chemotherapy.
A phase 2 study10 of geﬁ tinib (n=201) compared with 
placebo (INSTEP) in a group of patients with similar 
characteristics to those in TOPICAL showed no statistical 
diﬀ erence in survival with a HR of 0·84 (95% CI 
0·62–1·15), but we identiﬁ ed a suggestion of a beneﬁ t 
among patients with high EGFR gene copy number 
determined by ﬂ uorescence in-situ hybridisation 
(HR 0·44, 95% CI 0·17–1·12). 34 of the 100 patients in the 
geﬁ tinib group developed rash, and none with placebo, but 
the investigators did not analyse this ﬁ nding. The dose of 
geﬁ tinib might have been sub therapeutic in patients with 
wild-type EGFR tumours, and this notion is supported by 
the lower than expected proportion who developed rash. 
Another phase 2 trial29 of only patients of performance 
status 2 (n=103) with a median age of less than 70 years 
compared erlotinib with carboplatin and paclitaxel, and 
showed that progression-free survival was better with 
chemotherapy than with erlotinib but progression-free 
survival did not diﬀ er between patients assigned erlotinib 
who developed rash compared with those who were 
assigned chemotherapy (HR 0·94, 95% CI 0·56–1·59). In 
TOPICAL, erlotinib seemed to have a greater eﬀ ect in 
some subgroups than in others (eg, median overall survival 
was improved by 3·6 months for women with rash and 
1·1 months for men with rash). Previous studies have also 
reported sex–treatment interactions with tyrosine-kinase 
inhibitors and other chemotherapies, where female 
patients bene ﬁ ted more than men.30
Diarrhoea, hair loss, and fatigue were expected adverse 
events associated with erlotinib, and their severity was 
usually mild to moderate. Overall, occur rence and severity 
of adverse events in TOPICAL were much the same as 
those in the SATURN and BR.21 trials despite our 
population being predominantly elderly patients with 
poor performance status (ECOG 2–3).5,6 Taking erlotinib 
tablets at home should be more convenient to patients 
compared with treatments that require administration in 
hospital. Together with radiological assessment, ﬁ rst 
cycle erlotinib-induced rash could be used to select 
patients who are likely to beneﬁ t from continuous treat-
ment. We believe that patients with poor performance 
status and activating EGFR mutation tumours should 
Panel: Research in context
Systematic review
We did not do a systematic review of scientiﬁ c literature before designing the TOPICAL trial 
(in 2002), because at the time there were no other studies of ﬁ rst-line EGFR inhibitors in 
patients with advanced non-small-cell lung cancer (NSCLC) who were elderly or had poor 
performance status. These patients are often excluded from ﬁ rst-line chemotherapy trials.
Lung cancer is predominantly a disease of elderly people, and elderly patients with 
advanced NSCLC deemed unsuitable for chemotherapy with poor performance status 
(2 and 3) or several comorbidities, or both, remain a major challenge. Since TOPICAL, no 
phase 3 trials of ﬁ rst-line monotherapy for this group have been reported.
Interpretation
The ﬁ ndings of TOPICAL and other trials5–8 show that erlotinib is an important treatment 
for patients with NSCLC in various clinical settings, including as maintenance after 
ﬁ rst-line chemotherapy, as second-line or third-line monotherapy in unselected patients 
with advanced NSCLC, and in chemotherapy-naive patients with activating EGFR 
mutations. However, unlike the TOPICAL patients, most of the patients in other studies 
had good performance status.
The clinical implications of the TOPICAL trial are that patients who are deemed unsuitable 
for chemotherapy could be given erlotinib. Those who have EGFR mutation-positive 
tumours could receive continuous erlotinib; whereas those who have wild-type tumours 
should discontinue erlotinib after about 28 days if they do not develop a rash because of 
the possibility of decreased survival.
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receive erlotinib or geﬁ tinib, in line with the established 
evidence in patients with good per formance status, and 
supported by the ﬁ nding that the small number of these 
patients in TOPICAL all developed rash.7,8,14
Our data suggest patients with EGFR wild-type or 
unknown EGFR status tumours could start erlotinib but 
they should discontinue if they do not develop rash 
within 28 days, because these patients had no beneﬁ t in 
overall survival or progression-free survival, and in some 
subgroups overall survival could be reduced if erlotinib 
were taken continuously (panel). The reasons for this 
ﬁ nding are unknown but for some of our patients 
(especially men and  those with ECOG performance 
status of 3), the disease might be so advanced that any 
toxic treatment could accelerate deaths. Researchers 
have recorded deleterious eﬀ ects of anti-EGFR in some 
patients treated with erlotinib or cetuximab.31,32 A strategy 
of use of ﬁ rst-cycle erlotinib-induced rash to select 
patients with poor performance status for continued 
treatment could substantially improve cost eﬀ ectiveness. 
Erlotinib is expensive: a 30-day pack costs about £1650 in 
the UK ($4740 in the USA). Future analyses of TOPICAL 
will examine the cost eﬀ ectiveness of various approaches, 
and compare quality adjusted life-years. Second and 
third line erlotinib is marginally cost-eﬀ ective compared 
with best supportive care, therefore ﬁ rst-line erlotinib 
could be more cost-eﬀ ective.33
EGFR testing has now become standard of care to 
select patients who are EGFR mutation-positive for 
treatment with tyrosine-kinase inhibitors. If erlotinib is 
to become a standard therapy for patients who have 
EGFR wild-type tumours and are unsuitable for 
chemotherapy (93% in our trial) it should be in a selected 
population. Prospective studies are needed to increase 
our understanding of the biological mechanism linking 
rash and erlotinib beneﬁ t, including dose-escalation 
studies or studies of the relation between rash and 
tumour EGFR copy number.34 Further translational 
research with our biological samples might identify 
candidate markers for erlotinib-induced rash that can 
preselect patients for treatment with a marker measured 
at baseline, without having to treat all patients for 
4 weeks, and then discontinue those without rash.
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